Tag: GlobeNewswire

TORONTO, Nov. 02, 2026 (GLOBE NEWSWIRE) — GLOBEX MINING ENTERPRISES INC. (GMX – Toronto Stock Exchange, G1MN – Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz, LS Exchange, TTMzero, Düsseldorf and Quotrix Düsseldorf Stock Exchanges and GLBXF – OTCQX International in the US) is pleased to inform shareholders that it has increased the size of its contiguous GEM Hills claim block to 20 unpatented lode claims by staking in October 2026.

The project was initially acquired in October 2025 through the staking of 8 unpatented lode claims. It is situated on the eastern flank of the Clover Mountains in Lincoln County, southeastern Nevada, approximately 170 km linearly northeast of Las Vegas.

Each claim covers an area of 8.36 hectares, totalling a surface area of 167.22 hectares. All claims are located on Bureau of Land Management (BLM) public land and sit outside of any designated conservation areas.

Location map of Globex’s Gem Hills rare earth elements (REE) property. Also shown is the location of MP Materials Mountain Pass REE mine and the Virgin Mountain REE project (optioned from Globex to Lodestar Minerals). Mountain Pass accounted for approximately 12% to 14% of the world’s rare earth mined output (mainly LREE). The U.S. government, primarily through the Department of Defense (DoD), provides significant support to MP Materials’ Mountain Pass rare earth mine, all aimed at securing a domestic supply chain for defense and high-tech industries, reducing REE reliance on China, and boosting U.S. industrial independence.

Mining History, Geology and Sampling had been already described in Globex’s previous press release dated February 11, 2026. In the following only a short summary:

The Gem Hills Project covers rare earth element (REE) mineralization discovered during a 2024 regional prospecting campaign. The property is located outside any known mining district at the southeastern margin of the Caliente Caldera Complex of Tertiary age. Exploration in 2024 and 2025 including surface rock sampling, hand trenching, and dump sampling from 1930s era historic workings confirmed an initial mineralized footprint extending along a 90-meter strike length that remains open to the north and south.

The REE mineralization developed directly at the brecciated/faulted contact to Devonian limestone/dolomite, extending further away as a mixed clayey breccia zone of carbonate rock and volcanic rock with lower grades, locally extending also into argillic-phyllic altered volcanic rocks. Apparently, especially the carbonate fragments had been replaced by an REE rich mineral association and mostly, but not always, also by more or less abundant black manganese oxide minerals.

Mineralization Profile and Historical Sampling Highlights

The Gem Hills Project stands out for its high Total Rare Earth Oxide (TREO) grades, significant Heavy Rare Earth Element (HREE) enrichment, and an environmentally favourable, near-zero radiation profile.

Mineralization is characterized by a high-value suite of both Light Rare Earth Elements (LREE) specifically praseodymium and neodymium and critical HREE, including gadolinium, terbium, dysprosium, holmium, and erbium. Notable yttrium enrichment is also present, with assays reaching up to 0.435% Y₂O₃.

Core Sampling Results
Historical sampling from the autumn 2025 program (and one foundational 2024 sample) highlighted the following resource potential from 34 property wide rock samples:

• TREO Grades: 18 samples returned significant values ranging from 0.28% to 5.26% TREO, yielding a strong average of approximately 1.7% TREO.
• HREO Distribution: Heavy Rare Earth Oxides account for an average of 8% of the TREO (ranging up to 19%), with the highest heavy fractions concentrated in mine dump samples.
• High-Value REO Share: High value critical oxides (comprising premium HREO and LREO) average roughly 17% of the total mix, spanning from 1.5% up to 39.7%.
• Magnet Feedstocks (Nd+Pr): Combined Neodymium and Praseodymium (Nd₂O₃ + Pr₂O₃) average 13.7% of the TREO, hitting a peak combined grade of 1.14% (equivalent to 11.4 kg/t).
• Targeted HREE Enrichment: Premium elements like Dysprosium and Terbium show intense, localized enrichment, peaking at 0.09% Dy₂O₃ (0.9 kg/t) and 0.016% Tb₂O₃ (0.16 kg/t), respectively.

A Rare, Low-Radioactivity Advantage

Crucially, the Gem Hills mineralization features an absence of dangerous uranium and thorium anomalies, matching normal background radiation levels. While low-radioactivity REE deposits (such as carbonatites) typically lack the Heavy Rare Earth elements required by modern technology, Gem Hills combines an environmentally clean, low-radiation profile with a relatively high HREE share. This offers a unique, lower-cost, and safer pathway for critical metal recovery without the regulatory and environmental liabilities of high-radioactivity ores.

Ore Mineralogy & XRD Analysis

To determine the REE-rich ore mineralogy, three powdered samples were submitted to the Momentum Transfer laboratory for High-Resolution Synchrotron X-ray Diffraction (XRD) measurements. These analyses were performed at beamline ID31 at the European Synchrotron Radiation Facility (ESRF), and the final report was received on October 19, 2026.

The submitted channel samples represented varying grades and widths across three trenches:

• Sample H-07: 1.889% TREO (0.60 m channel sample from Trench E)
• Sample H-25: 2.281% TREO (0.95 m channel sample from Trench C)
• Sample H-29: 2.642% TREO (1.75 m channel sample from Trench B)

The relative abundance of the major, minor, and trace mineral phases calculated from the powdered samples revealed the following mineralogical profile:

• Major Mineral Phases: Calcite, aragonite, dolomite, nacrite (26%–46%), gibbsite (0.25%–10%), and nordstrandite (0%–17%). Nacrite (Al2Si2O5(OH)4) is the highest temperature polytype of the kaolin group, exclusively requiring hydrothermal or pneumatolytic processes to precipitate. Gibbsite and nordstrandite are polymorph minerals sharing the same chemical formula, Al(OH)3.
• Minor Mineral Phases: Quartz and fluorite. Notably, fluorite is relatively abundant, reaching up to 9.6%. Because it is invisible to the naked eye or a hand lens, it is interpreted to be finely dispersed as microscopic grains within the ore matrix.
• Trace and Additional Phases: Manganese oxides (lithiophorite and cryptomelane), iron oxides (hematite and goethite), sphalerite (0.5%–2.4%), alunite (0%–0.8%), Na-mica (likely illite), smectite (montmorillonite), and traces of all three TiO2 polymorphs (anatase, rutile, and brookite).

REE Hosting Mechanism

Bastnaesite was the only discrete REE mineral phase detected, occurring in trace amounts up to 0.18%. Consequently, the bulk of the REE mineralization (>90%) is adsorbed to the clay minerals nacrite, gibbsite, and nordstrandite, with a minor fraction potentially hosted within fluorite.

Macroscopically, abundant clay like minerals (up to 50%) characterize the project’s signature “black & white mottled breccia” ore. The XRD results confirm that the white patches consist of nacrite, gibbsite, and nordstrandite, while the surrounding black matrix is a mixture of manganese oxides and carbonate minerals.

Genetic Model for Gem Hills

Based on the local geological setting and mineral assemblages, a comprehensive genetic model has been established.

The Gem Hills Rare Earth Element (REE) mineral occurrence represents a highly localized, multi-stage magmatic-hydrothermal system telescoped by late-stage regional fluids and overprinted by a district-scale caldera-wide alteration system. The deposit is structurally localized along a near vertical NW-SE fault zone near to a Tertiary caldera rim, acting as a focused chemical trap at the contact between reactive Paleozoic carbonate rocks to the west and calc-alkaline rhyolite & latite to the east.

The formation of the Gem Hills REE mineralization occurred across three overlapping (telescoped) hydrothermal stages:

• Stage 1: Deep Alkaline Magmatic-Hydrothermal Input — Initial injection of magmatic fluids derived from alkaline monzonite-syenite intrusion exsolving highly incompatible fluids rich in F, CO₂, LREE, and HREE.
• Stage 2: Waning Advanced Argillic Overprint & REE Adsorption Trap — Acidic, cooler hydrothermal fluids created the relatively high-temperature nacrite and aluminum hydroxides, establishing the perfect clay-adsorption environment to trap the migrating rare earth elements.
• Stage 3: District-Scale Caldera Vapor-Phase & Regional Oxidized Fluid Event — Late-stage overprinting by regional oxidized fluids introducing the abundant manganese and iron oxides that form the breccia’s dark matrix.

Paragenetic Sequence Chart

Mineral Phase / Event	Stage 1: Magmatic-Hydrothermal	Stage 2: Waning Advanced Argillic	Stage 3: District-Scale Late Caldera
Dolomite / Calcite	— — —	• • • • (Dissolution/Relict)	• • • • (Dissolution/Relict)
Fluorite (Fine dispersed)	— — — — — — — —	— — — —	— visible cubes, recrystallized
Sphalerite	— — — — — —
Bastnäsite	— — — — (Primary)	• • • • (Dissolution/Relict)
Nacrite		— — — — — — — — (Mod-High T)
Gibbsite		— — — — — — — — (Low T)
Nordstrandite		— — — — — — — — (Very Low T)
REE Adsorption (HREE & LREE)		====================
Alunite & Silica (High-Elevation Cap)			— — — — — — — — (Vapor-phase)
Cryptomelane / Lithiophorite (with Li, Co, Ni)			— — — — — — — — (Matrix)
Limonite (Goethite) & Chalcedony			— — — — — — — — (Distal fissures)
Fluid Character:	Magmatic, Acidic, F-CO₂ Rich	Hydrothermal Cooling, Acidic	Regional, Oxidized, Weakly Hydrothermal
Thermal Regime:	High Temperature	Progressive Decline (Moderate to Low)	Weakly Elevated (50°C–100°C) to Boiled Vapor

Legend:
— — —           Continuous mineralization/deposition
• • • •                Dissolution, corrosion, or relict phase existence
======           Main Ore Stage / Peak element concentration event

Classification and Deposit Type

The Gem Hills REE mineralization stands alone and may represent an entirely new class of hydrothermal-metasomatic REE ion-adsorption clay deposits. While typical ion-adsorption deposits are regolith hosted, relying on slow, surface weathering processes that yield low grades, Gem Hills stands out by delivering exceptionally high REE grades generated through a robust, multi-stage hydrothermal system. This distinctive genetic origin positions Gem Hills as a highly unique target with potentially disruptive economics for the critical minerals sector.

A Highly De-Risked Strategic Opportunity

If an economic orebody is outlined, combining Nevada’s tier-one mining jurisdiction with a high-grade, potentially easily processable, and relatively clean orebody, the Gem Hills Project represents a highly de-risked opportunity for potential direct federal funding, forward-purchasing agreements, and strategic DoD price floor guarantees. Management believes these attributes significantly elevate the project’s valuation and attractiveness to potential option partners seeking to secure long-term domestic supply.

The Gem Hills Project combines an exceptional heavy rare earth element (HREE) enrichment profile with highly favorable preliminary mineralogical and environmental indicators. X-ray diffraction (XRD) analysis has confirmed that the REE mineralization is hosted within a hydrothermal-metasomatic, ion-adsorption style setting associated with nacrite, gibbsite, and nordstrandite. Unlike refractory hard-rock deposits (such as bastnäsite or monazite) that require energy intensive, highly complex chemical cracking, the Gem Hills REE are bound via a unique hydrothermal-metasomatic mechanism to nacrite, gibbsite, and nordstrandite. This mineralogical architecture, subject to additional detailed metallurgical test work and positive results, could be expected to allow for significantly milder, lower cost leaching processes  with a reduction in both CapEx and OpEx for processing infrastructure.

Furthermore, initial geochemical sampling indicates an exceptionally clean environmental profile, with baseline thorium levels remaining below 20 ppm alongside very low uranium values. Management believes these combined technical attributes substantially de-risk early-stage exploration variables, positioning Gem Hills as a premier candidate for systematic advancement.

As a project generator, Globex options projects to qualified strategic partners equipped to fund and execute the next phases of exploration, including systematic drilling and formal metallurgical bench testing. While early indicators align closely with the criteria prioritized by U.S. federal funding mechanisms such as the Defense Production Act (DPA) Title III and Department of Energy (DOE) critical mineral grants, the primary near-term focus will be either the execution of a definitive option agreement to advance the project’s technical and economic baseline frameworks or work programs funded by Globex.

This press release was prepared by Matthias Jurgeit, Eurogeologist under the supervision of Jack Stoch, P.Geo., CEO & Executive Chairman of Globex in his capacity as a Qualified Person (Q.P.) under NI 43-101.

We Seek Safe Harbour.	Foreign Private Issuer 12g3 – 2(b)
	CUSIP Number 379900 50 9 LEI 529900XYUKGG3LF9PY95
For further information, contact:
Jack Stoch, P.Geo., Acc.Dir. CEO & Executive Chairman Globex Mining Enterprises Inc. Suite 219, 120 Carlton Street Toronto, Ontario, Canada, M5A 4K2	Tel.:  819.797.5242 Fax:  819.797.1470  info@globexmining.com  www.globexmining.com

Caution Regarding Forward-Looking Statements

Certain statements included in this press release may constitute “forward-looking statements” within the meaning of applicable Canadian securities laws. Except as may be required by such laws, Globex Mining Enterprises Inc. (“Globex”) does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements, by their very nature, are subject to numerous risks and uncertainties. As a result, actual results could differ materially from Globex’s expectations expressed in or implied by such forward-looking statements. No assurance can be given that any events anticipated by the forward-looking statements will materialize, or if any of them do, what benefits Globex will derive therefrom. Numerous risk factors which may cause actual results to differ materially from expectations expressed in or implied by the forward-looking statements are discussed in Globex’s annual information form for the 2025 fiscal year filed with the Canadian securities regulatory authorities, available on SEDAR+ at www.sedarplus.ca and on Globex’s website at www.globexmining.com. Globex cautions readers that such risks are not the only ones that could impact it. Additional risks and uncertainties not currently known to Globex or that Globex currently deems to be immaterial may have a material adverse effect on Globex’s business, financial condition, and results of operations. Given these risks and uncertainties, Globex cautions investors and others against placing undue reliance on such forward-looking statements as a prediction of future results or for any other purpose. This press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein have not been and will not be registered under the Securities Act of 1933, as amended (the “1933 Act”), or with any securities regulatory authority of any state or other jurisdiction in the United States, and may not be offered or sold, directly or indirectly, within the United States or to, or for the account or benefit of, U.S. persons (as such term is defined in Regulation S under the 1933 Act), except pursuant to an exemption from or in a transaction not subject to the registration requirements of the 1933 Act.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3889d05f-efe3-4a69-b266-5348a5ed978f

CARSON CITY, Nev., Nov. 02, 2026 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the Company has been invited to present a late-breaking oral presentation at the 4th Long COVID International Conference 2026 to be held in Nice, France from November 12-13, 2026.

Dr. Penelope Markham, BioVie’s Senior Vice President and Program Lead for Long COVID, will share the presentation titled “Bezisterim Improves Fatigue, Post-Exertional Malaise, and Cognition in Prespecified High-Symptom-Burden Subgroups of the Phase 2 Randomized ADDRESS-LC Trial in Long COVID” during the “Session 8: Clinical Trials” session, starting 3:30 p.m. on Friday, November 13. The presentation will include new biomarker data that has not been shared previously.

The ADDRESS-LC trial, a randomized, placebo-controlled signal seeking, exploratory study, showed treatment with bezisterim showed a consistent trend toward improvement across most patient-reported and objective efficacy measures compared with placebo. In pre-specified, exploratory analyses, patients with more severe baseline fatigue, post-exertional malaise (PEM), or objective cognitive impairment – symptoms affecting approximately 78% of trial participants in at least one domain – experienced the greatest benefits with bezisterim, including statistically significant improvements in multiple measures corresponding to their most pronounced symptoms.

“We look forward to presenting initial biomarker data at the upcoming Long COVID conference that are consistent with the clinical findings observed in ADDRESS-LC,” said Penelope Markham, BioVie’s Senior Vice President and Program Lead for Long COVID. “The biomarkers provide further biological support for the potential of bezisterim in treating Long COVID. Our Trial observed a consistent and clinically coherent pattern of improvement across measures of fatigue, post-exertional malaise, clinician- and patient-reported outcomes, and objective measures of cognition function among patients with greater baseline symptom burden.”

About Long COVID

An estimated 17-20 million U.S. adults reported to be living with Long COVID,¹ with 3.8 million experiencing significant limitation to their daily lives.² Almost 50 percent of those with Long COVID develop persistent or intermittent symptoms.³ The neurological and neuropsychiatric symptoms are among the most common and disabling manifestations of the condition and include fatigue, PEM, sleep disturbance, and persistent sense of difficulty with thinking and memory.⁴ Chronic innate inflammation accompanied by ongoing immune dysregulation is among the leading hypotheses proposed to explain the symptoms in Long COVID, with numerous investigators describing findings in Long COVID that appear to be supportive of the intended biological targets of bezisterim. Currently, there are no FDA-approved treatment options for Long-COVID.

About the ADDRESS-LC trial

The Phase 2 ADDRESS-LC study (NCT06847191), which is fully funded by a grant from the U.S. Department of War (DoW), is a randomized (1:1), placebo-controlled, signal-finding proof-of-concept, multicenter trial evaluating the efficacy, safety and tolerability of bezisterim in adult participants with Long COVID who have cognitive impairment sequelae and fatigue. The study compared bezisterim, administered as a 20 mg oral capsule twice daily, with a matching placebo to assess its effects on neurocognitive and fatigue-related symptoms. The trial evaluated 22 clinical outcome measures, with no single endpoint pre-specified as the primary determinant of study success. Endpoints include assessing changes in overall clinical benefit, subjective and objective cognitive function, fatigue, sleep disturbance, Quality of Life and PEM. As a signal-finding study, the trial was designed to identify efficacy signals, measure treatment effect magnitude, and identify patient subgroups most likely to benefit, to inform the design of future Phase 3 trials

About Bezisterim

Bezisterim (NE3107) is an investigational oral drug that crosses the blood-brain barrier and works to reduce inflammation and improve insulin sensitivity without suppressing the immune system and with a low risk of drug-drug interactions. By modulating key pathways involved in neuroinflammation (ERK, NFκB, TNFα), bezisterim may have therapeutic potential in several disease indications, including Parkinson’s disease (PD), Long COVID (LC), and Alzheimer’s disease (AD).

In PD, BioVie completed the SUNRISE-PD trial, which enrolled 57 patients to establish proof of mechanism and proof of concept in individuals with early-stage disease who had not previously been treated with carbidopa/levodopa. Topline results showed that patients treated with bezisterim experienced improvements with blood-based markers of inflammation, as well as a broad range of biomarkers associated with cellular health and neuronal integrity. Clinically, patients treated with bezisterim demonstrated greater improvements than those receiving placebo across multiple measures of daily functioning, motor symptoms, and non-motor symptoms.

For LC, the ADDRESS-LC trial enrolled approximately 200 patients to evaluate whether bezisterim may help reduce brain fog, fatigue, and other lingering neurological symptoms associated with LC. The hypothesis being studied is that these symptoms may be triggered by persistent circulation of spike protein fragments that trigger inflammation via NFκB activation (which bezisterim has been shown to modulate).

In AD, BioVie has conducted Phase 2 and Phase 3 trials. Preliminary data from these trials suggest improvements in cognition and biomarkers, supporting further trials to evaluate its potential as a therapy for the six million Americans living with AD.

Terms of the U.S. Department of War (DoW) Award

The Long COVID study is supported by the Assistant Secretary of War for Health Affairs and endorsed by the DoW by a fully funded award in the amount of $13.13 million through the Peer-Reviewed Medical Research Program (PRMRP) under Award No. HT9425-24-1-0113. Opinions, interpretations, conclusions and recommendations in this press release are those of the author and are not necessarily endorsed by the Assistant Secretary of Defense for Health Affairs or the DoW.

About BioVie Inc.

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage biopharmaceutical company focused on developing therapies for neurological disorders and advanced liver disease. Its lead investigational drug candidate, bezisterim (NE3107), targets neuroinflammation and insulin resistance, which are believed to be key drivers of Alzheimer’s and Parkinson’s disease. Bezisterim is also being studied for Long COVID, where persistent inflammation is thought to underlie symptoms such as brain fog and fatigue.

In liver disease, BioVie is advancing BIV201, a continuous infusion of terlipressin treatment that has received FDA Orphan and Fast Track designations. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis, and the Company plans to study BIV201 in a Phase 3 trial for the reduction of further decompensation in patients with cirrhosis and ascites. For more information, visit www.bioviepharma.com.

Forward-Looking Statements

This press release contains forward-looking statements, which may be identified by words such as “expect,” “look forward to,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “project,” “potential,” “may,” or words of similar meaning. Forward-looking statements in this release include, but are not limited to, statements regarding: the potential for bezisterim to address unmet clinical needs in Long COVID and Parkinson’s disease; the design and conduct of future clinical trials, including a potentially pivotal Phase 3 trial; the potential clinical significance of subgroup analyses and biomarker observations; and the Company’s ability to advance bezisterim through clinical development. The clinical endpoints reported in this release are exploratory in nature. The Phase 2 ADDRESS-LC trial did not achieve statistical significance on any endpoint in the overall intent-to-treat population; statistically significant results were observed only in pre-specified subgroup analyses. Subgroup analyses are hypothesis-generating and may not be replicated in future trials. Changes in biomarkers may not correlate with clinical benefit or support regulatory approval. The FDA has not validated these endpoints as surrogate endpoints for Long COVID. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to risks related to the early stage of development of bezisterim and other product candidates, the possibility that results observed in this Phase 2 study of 203 patients may not be replicated in larger or longer-duration trials, the exploratory nature of subgroup analyses, the Company’s ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, the possibility that clinical trial results may not be indicative of results in subsequent or larger trials, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company’s control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.

For Investor Relations Inquiries:

Contact:
Chuck Padala
Managing Director, LifeSci Advisors, LLC
chuck@lifesciadvisors.com

For Media Inquiries:

Contact:
Melyssa Weible
Managing Partner, Elixir Health Public Relations
mweible@elixirhealthpr.com

_____________________________
¹ U.S. Department of Health and Human Services (https://www.hhs.gov/longcovid/index.html)
² Bonuck et al. Commun Med. 2026;6:177. doi:10.1038/s43856-026-01516-7.
³ Thaweethai et al. Nat Commun. 2025;16(1):9557. doi:10.1038/s41467-025-65239-4.
⁴ Geng et al. JAMA. 2025 Feb 25;333(8):694-700. doi: 10.1001/jama.2024.24184.

Two oral presentations mark Afirma’s strongest podium presence in recent years, alongside eight posters

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) — Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that 10 abstracts involving its Afirma thyroid test will be presented at the 2026 Annual Meeting of the American Thyroid Association (ATA), November 4–7 in Philadelphia. The conference includes two oral presentations and eight posters, with five studies conducted independently of Veracyte.

The studies explore how gene expression can provide insights beyond individual genetic alterations to inform thyroid nodule diagnosis and assessment of cancer aggressiveness. Oral presentations from Johns Hopkins and MD Anderson will examine potential imaging and treatment targets. Posters include studies using the Veracyte Genomic Resource for Intelligent Discovery (GRID) research database to investigate preoperative diagnosis and recurrence risk, as well as independent research on molecular testing and long-term outcomes.

“Patients facing a thyroid nodule diagnosis need to know whether they have cancer and, if they do, how that cancer might behave,” said Phillip Febbo, M.D., Veracyte’s chief scientific and medical officer. “These studies build on Afirma’s long-established role in thyroid nodule diagnosis and explore how gene expression data can help researchers answer additional questions about cancer risk and biology.”

Afirma-related presentations at ATA 2026

Oral presentations

Title: Prostate-Specific Membrane Antigen (PSMA) mRNA Expression in Thyroid FNA Samples with Bethesda III-VI Cytology Predicts Lymphatic and Angioinvasion in Surgically Resected Tumors

• Presenter: Wasim Najjar, MD, and Prasanna Santhanam, MD, Johns Hopkins University
• Abstract #: O37
• Date and time: Friday, November 6, 5:30-5:45 p.m. EST
• Location: Salon H

Title: MRNA Analysis of Cell-Surface Protein Targets in Medullary Thyroid Cancer Fine Needle Aspiration Samples

• Presenter: Sarah Hamidi, MD, MD Anderson Cancer Center
• Abstract #: O27
• Date and time: Thursday, November 5, 5:30-5:45 p.m. EST
• Location: Salon H

Poster presentations

Title: Preoperative Transcriptomic Predictors of Benign or Malignant Thyroid Tumors without Expressed Variants and Fusions

• Presenter: Eisha Gupta, MD and Arti Bhan, MD, Henry Ford Health
• Abstract #: P311
• Date and time: Friday, November 6, 2:15-3:15 p.m. EST
• Location: Franklin Hall

Title: Preoperative Thyroid Nodule MRNA Expression Signatures to Predict 2025 Ata Risk of Recurrence for Differentiated Thyroid Cancer

• Presenter: Eisha Gupta and Arti Bhan, Henry Ford
• Abstract #: P310
• Date and time: Friday, November 6, 2:15-3:15 p.m. EST
• Location: Franklin Hall

Title: KEAP1 and NFE2L2 Mutations Drive NRF2 Pathway Activation in Indeterminate and Malignant Thyroid Nodules

• Presenter: Taylor Cavazos, PhD, Veracyte, and Nicholas Bambach, MS, Children’s Hospital of Philadelphia
• Abstract #: P229
• Date and time: Thursday, November 5, 2:45-3:45 p.m. EST
• Location: Franklin Hall

Independent poster presentations

Title: Invasion Signature Stratifies Malignancy and Invasive Pathology in Variant-Positive Indeterminate Thyroid Nodules

• Presenter: David Allen, MD, New York Medical College
• Abstract #: P145
• Date and time: Thursday, November 5, 10:30-11:30 a.m. EST
• Location: Franklin Hall

Title: Long-Term Follow-Up of Cytologically Indeterminate Afirma Gene Sequencing Classifier (GSC) Benign Nodules

• Presenter: Janevi June Rebernigg, Sarasota Memorial Healthcare System
• Abstract #: P326
• Date and time: Friday, November 6, 2:15-3:15 p.m. EST
• Location: Franklin Hall

Title: Long-Term Assessment of “Benign” Molecular Test Results in Indeterminate Thyroid Nodules: Should We Be Monitoring More Closely?

• Presenter: Justin Bauzon, MD, Cleveland Clinic Foundation
• Abstract #: P298
• Date and time: Friday, November 6, 2:15-3:15 p.m. EST
• Location: Franklin Hall

Title: Clinical Utility of Molecular Profiling in Nodules with Suspicious for Malignancy or Malignant Cytology

• Presenter: Gilman Plitt, MD, PhD, Cleveland Clinic Foundation
• Abstract #: P296
• Date and time: Friday, November 6, 2:15-3:15 p.m. EST
• Location: Franklin Hall

Title: Prevalence and Predictive Factors of Malignancy in Cytologically Indeterminate RAS-Mutant Thyroid Nodules

• Presenter: Nathalie Silva De Morais, MD, PhD, Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Mass General Brigham, Harvard Medical School
• Abstract #: P615
• Date and time: Friday, November 6, 2:15-3:15 p.m. EST
• Location: Franklin Hall

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care. Veracyte’s Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development. The company’s portfolio includes the Afirma® Genomic Sequencing Classifier test, Decipher® Bladder Genomic Classifier test, Decipher® Prostate Genomic Classifier test, Prosigna® Breast Risk of Recurrence test, and the TrueMRD™ Monitoring Test for MIBC. For more information, visit Veracyte’s website or follow the company on LinkedIn or X (Twitter).  

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, our statements related to the potential for gene expression analysis to inform thyroid nodule diagnosis and the assessment of cancer aggressiveness and recurrence risk and the potential for GRID to support research into thyroid cancer risk and biology. Forward-looking statements can be identified by words such as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will,” “enable,” “positioned,” “offers,” “designed,” “ultimately,” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 26, 2026, as well as in other documents that we may file from time to time with the Securities and Exchange Commission. Copies of these documents, when available, may be found in the Investors section of our website at Veracyte Investor Relations. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Investors: 
Kelly Gura  
investors@veracyte.com

Media: 
Molly Cornbleet 
media@veracyte.com 
+1 650-351-8780

BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of November/this quarter.

Details are as follows:

Guggenheim 3rd Annual Healthcare Innovation Conference
Date: Monday, November 9, 2026
Time: 1:30 PM ET
Webcast Link: https://event.summitcast.com/view/

Stifel 2026 Healthcare Conference
Date: Wednesday, November 11, 2026
Time: 11:20 AM ET
Webcast Link: https://event.summitcast.com/view/

Virtual/Replay availability: Presentations will be archived on Compass’ Events page.

Compass’ management will be available for one-on-one meetings during all events. Interested investors should contact their respective representatives to request meetings.

About Compass Therapeutics
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company dedicated to transforming the standard of care for patients with cancer through the discovery and development of innovative antibody-based therapeutics. The company leverages deep expertise in tumor biology and proprietary antibody engineering technologies to develop differentiated therapies that target the intersection of angiogenesis, immune activation, and tumor-driven immunosuppression. Compass has a robust pipeline of novel product candidates designed to address significant unmet needs and improve outcomes for patients with cancer. The Company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com

Investor Contact
ir@compasstherapeutics.com

Media Contact
Anna Gifford, Chief of Staff
media@compasstherapeutics.com
617-500-8099

Agreement delivers AI-powered narrative open-source intelligence to understand narratives across social platforms, strengthening situational awareness and threat assessment surrounding major regional events

New York, NY, Nov. 02, 2026 (GLOBE NEWSWIRE) — Cyabra, Inc. (Nasdaq: CYAB) (“Cyabra“ or the ”Company“), an artificial intelligence (“AI“)-powered narrative intelligence company that helps governments and enterprises detect coordinated manipulation and protect digital trust, today announced a new six-figure agreement to provide its platform to a national investigative and law enforcement agency in Southeast Asia.

Under the terms of the agreement, the agency’s investigative teams will use Cyabra’s narrative open-source intelligence, built on publicly available data, to analyze online narratives, detect coordinated activities, and evaluate evolving information trends. The deployment is designed to give investigative teams a clear, timely read on potential threats and security risks around major regional events.

As national security and law enforcement agencies worldwide face sophisticated digital influence operations, they are increasingly prioritizing evidence-based narrative intelligence to detect manufactured activity and protect public confidence.

The deployment equips the investigative agency with capabilities to assess digital risk surrounding public gatherings and high-profile regional events:

• Event-Driven Risk Assessment: Identifying emerging digital narratives and evaluating potential threat vectors in advance of and during major regional events, summits, and high-visibility public gatherings.
• Coordinated Behavior Detection: Surfacing inauthentic, coordinated accounts and state-linked troll farms, orchestrating digital manipulation to distort public sentiment or provoke unrest.
• Proactive Threat Intelligence: Providing actionable early warnings by tracking velocity, sentiment shifts, and cross-platform amplification of harmful content before online campaigns escalate.
• Enhanced National Security Preparedness: Delivering defensible, evidence-based reporting that empowers operational commanders and analysts to transition from reactive responses to proactive mitigation.

“Public trust is being shaped by inauthentic accounts and coordinated networks most people can’t see, and for investigative agencies, defending it starts with separating the real from the manufactured,” said Dan Brahmy, Co-Founder and CEO of Cyabra. “We believe Cyabra gives investigators the decision-grade clarity needed to protect public safety and critical institutions.”

This agreement marks another significant milestone in Cyabra’s ongoing expansion across the international public sector, building upon recent multi-year sovereign contracts and enterprise deployments across the Asia-Pacific region. By delivering cloud-native, high-security software tailored to defense, intelligence, and law enforcement frameworks, Cyabra provides the evidence, while the judgment, the authority, and the decision stay with the agency.

About Cyabra

Cyabra is an AI-powered narrative intelligence company that helps national security and defense organizations, government agencies, brands, communications agencies, and global enterprises restore trust and authenticity online by analyzing manipulated content, coordinated behaviors, and inauthentic actors. The platform helps teams understand who is operating, how activity is amplified, and where coordinated activity is shaping perception, translating evidence into clear mitigation steps. By reducing ambiguity and misdirected response, Cyabra enables proportionate, evidence-led action when clarity matters most.

For more information, visit www.cyabra.com.

Contact:

Investors: ir@cyabra.com

Media: pr@cyabra.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical statements of fact and statements regarding Cyabra’s intent, belief, or expectations, including, but not limited to, statements regarding Cyabra’s future results of operations and financial position, planned products and services, business strategy and plans, market size and growth opportunities, competitive position and market trends. Some of these forward-looking statements can be identified by the use of forward-looking words, including ”may”, ”should”, ”expect”, ”intend”, ”will”, ”estimate”, ”anticipate”, ”believe”, ”predict”, ”plan”, ”targets”, ”projects”, ”could”, ”would”, ”continue”, ”forecast“ or the negatives of these terms or variations of them or similar expressions. For example, the Company is using forward-looking statements in this press release when it discusses the anticipated deployment and benefits of its platform under the agreement, its ability to support investigative and national security operations, that securing the agreement reflects its accelerating momentum across the Asia-Pacific region and its continued expansion across the international public sector and Asia-Pacific region. These statements relate to future events and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in Cyabra’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. Cyabra undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

The AI-native editor combines hands-on visual control, standard React code and an open workflow connected to every modern AI tool

 Built for agencies to take on more ambitious work and grow their businesses

NEW YORK — Wix.com Ltd. (NASDAQ: WIX) today announced Studio Two, one of the most advanced editors in the company’s history. Studio Two is an open, AI-native system in which generating with AI, designing on the canvas and working in standard React code become one continuous way of building a site. The work is portable, so professionals can bring projects into Wix, take them out as standard code and bring them back, and run the finished site on Wix or deploy it anywhere they choose. For agencies, that opens the door to larger and more complex projects, with Wix’s infrastructure and business solutions available whenever they need them.

With Aria 2.0, the new version of Wix’s AI agent, professionals can generate and refine designs, create custom components, connect data and complete complex tasks, then continue on the canvas with pixel-level precision or edit the code directly. With Skills, they can save instructions and workflows once so Aria 2.0 consistently applies their standards across every project. AI accelerates the work, but the professional remains the creative director.

Studio Two is a truly open creation platform. Professionals can build with any AI tool, import projects into Wix, and export them as standard React projects to continue building in Claude, Codex, Cursor or any IDE, then bring them back for visual refinement, all while leveraging Wix’s native business solutions, with security, compliance and infrastructure handled out of the box. This openness extends to individual components: any component not natively available in Studio Two can be created on an external platform and imported, removing the constraints of a fixed component library. Sites can run on Wix’s managed infrastructure and business solutions, or be deployed outside Wix entirely, opening enterprise opportunities and new markets for agencies. The platform is also built for AI agents: MCP-powered capabilities let agents interact with and manage Wix business solutions like Wix stores and Wix Bookings.

Studio Two is built on the same foundation as Wix Harmony, the AI-native platform Wix launched this year for DIY users. The shared architecture lets Wix ship new capabilities faster across both products and opens a new funnel for partners. Partners can open any Wix Harmony site in Studio Two and continue working on it with the full range of advanced capabilities. This enables a real value for partners as a new source of leads, DIY users who need further assistance can be seamlessly handed off to them.

“We listened to our Partners’ feedback and built Studio Two around their needs. AI enables professionals to do much more, they can take on more work, grow their businesses and help clients with more than just their websites. The value of Partners will increase, but their role will evolve. Studio Two gives them an open platform to make that transition, combining the power of AI with the tools and infrastructure to deliver complete solutions for their clients,” said Avishai Abrahami, Co-Founder and CEO of Wix.

Highlights of  Studio Two include:

• Truly open creation: Build with any AI tool, import projects into Wix, and export them to continue building or deploying elsewhere.
• The most advanced Wix editor ever: Every Studio Two capability, rebuilt on an open, AI-ready foundation shared with Wix Harmony.
• AI and hands-on design in one editor: Use Aria 2.0 to generate and refine a site, then switch to drag-and-drop editing to control every detail.
• Powerful new tools: Advanced visual editing on an infinite canvas, vibe coding, advanced animations, variables, site styles, automatic responsiveness and more.
• Built for AI agents: MCP-powered capabilities enable AI agents to manage nearly every aspect of a website and its business.
• Skills: Save instructions and workflows once, so Aria 2.0 applies your standards across projects without repeating tasks.
• A code layer for custom work: Generate or edit React components with Aria 2.0, or work directly in the browser-based Visual Studio Code environment.
• Business functionality built in: Customize the design of Wix Stores, Wix Bookings and other solutions, and add functionality with drag-and-drop components that automatically connect to live data.
• Enterprise opportunities: Export and deploy projects outside Wix, opening new markets and use cases.

“Studio Two brings together the things professionals need to do their best work. They can start with AI, work visually on the canvas, or go into code, and move between those approaches as the project requires. They stay in control of the result, while Wix provides the tools to make that work ready for clients,” said Gali Erez, VP Studio Two at Wix.

Studio Two is rolling out to Wix Partners, followed by a gradual rollout to all users. Existing Wix Studio sites remain supported, and partners can continue creating sites in both editors during the rollout.

For more information, visit https://www.wix.com/studio/studio-two.

About Wix.com Ltd. 

Wix’s vision is to simplify complex technologies and deliver the best tools for every type of user and business to create online. Powered by advanced AI and enterprise-grade infrastructure, Wix is trusted by millions of users worldwide. Founded in 2006 and strengthened by the acquisition in 2025 of Base44, the no-code application platform, Wix is continuing to build for the future of the internet. For more about Wix, please visit our Press Room. Media Relations Contact: PR@wix.com

For more about Wix, please visit our Press Room. 
Media Relations Contact: PR@wix.com

Attachments

• AI and hands-on design in one editor
• Context
• AI and hands-on design in one editor
• Powerful new tools
• A code layer for custom work

Five-year facility refinances existing borrowings and provides additional capacity to support acquisitions and general corporate purposes

WASHINGTON, Nov. 02, 2026 (GLOBE NEWSWIRE) — Public Policy Holding Company, Inc. (“PPHC”, the “Group” or the “Company”) (Nasdaq: PPHC), a leading global strategic communications provider offering a comprehensive range of advisory services in Government Relations, Public Affairs and Corporate Communications, announces that it has entered into a new $105 million senior secured credit facility with a U.S. commercial bank (the “New Facility”).

The New Facility comprises a $65 million term loan and a $40 million revolving credit facility. The Group intends to seek commitments from additional lenders through a syndication to increase the New Facility to an aggregate $150 million. The New Facility may include an additional uncommitted accordion option of up to $50 million. Syndication is being undertaken on a best-efforts basis and is currently anticipated to close in January 2027.

Key Terms

• A five-year senior secured facility comprising a $65 million term loan and a $40 million revolving credit facility at initial closing.
• Expected syndication to a total facility size of $150 million, anticipated to close in January 2027 on a best-efforts basis.
• An uncommitted accordion option of up to an additional $50 million, subject to lender approval and the satisfaction of applicable conditions.
• Interest payable at the Secured Overnight Financing Rate (“SOFR”) plus a margin of 185 to 230 basis points, determined by the Group’s net leverage ratio. An unused commitment fee of 15 to 25 basis points applies to undrawn revolving commitments, also based on net leverage.
• Term loan amortization, stated as a percentage of the original balance, of 5.0% in each of years one and two, 7.5% in each of years three and four, and 10.0% in year five, with the remaining balance due at maturity on November 2, 2031. The revolving credit facility is interest only.
• Secured by a blanket lien over the Group’s assets, with guarantees from substantially all subsidiaries.

Use of Proceeds

The proceeds of the New Facility will be used to refinance the Group’s existing debt, fund acquisitions including an immediate drawdown to fund the initial cash consideration for the acquisition of Reevemark LLC announced earlier today and provide additional capacity for working capital and general corporate purposes.

Existing Facilities

The Group’s existing borrowings under the credit arrangements first announced on March 1, 2023, and subsequently expanded and amended on April 30, 2024, June 6, 2024, and January 24, 2025, will be repaid and replaced by the New Facility shortly after closing. As of September 30, 2026, approximately $39.8 million was outstanding under the existing facilities.

Capital Allocation

The New Facility consolidates the Group’s borrowings into a single financing structure on more favorable terms, extends the Group’s debt maturity profile, and provides additional capacity to support its growth strategy.

The Group intends to maintain a prudent leverage ratio as it combines organic growth with targeted, earnings-accretive M&A. The PPHC Board of Directors considers that access to both debt and equity funding provides appropriate flexibility in the Group’s capital allocation, including the funding of acquisitions and deferred consideration, as well as the payment of dividends.

Stewart Hall, CEO of PPHC, commented:

“This new facility strengthens our financial position and provides additional capacity to execute our growth strategy while maintaining a disciplined approach to leverage and capital allocation. We remain focused on deploying capital selectively into opportunities that enhance our capabilities, broaden our geographic reach and create long-term value for shareholders.”

B/T Advisory acted as exclusive debt advisor, and Venable LLP acted as legal counsel to the Group. Further details of the New Facility, including the identity of the lender and a copy of the credit agreement, will be set out in a Current Report on Form 8-K to be filed with the U.S. Securities and Exchange Commission, which will be available at www.sec.gov and on the Company’s investor relations website.

About PPHC

Incorporated in 2014, PPHC is a global strategic communications platform that supports clients in enhancing and defending their reputations, advancing policy objectives, managing regulatory risk, and engaging with federal and state-level policymakers, stakeholders, media, and the public.

Engaged by approximately 1,500 clients, including companies, trade associations and non-governmental organizations, PPHC is active in all major sectors of the economy, including healthcare and pharmaceuticals, financial services, energy, technology, telecommunications and transportation.

With operations across 18 offices in the United States and internationally, PPHC’s services include government relations, public affairs and corporate communications, research and analytics, digital advocacy campaigning, and compliance support. The Company’s shares are admitted to trading on the Nasdaq Global Market and on AIM, a market operated by the London Stock Exchange, under the ticker symbol “PPHC”.

For more information, visit www.pphcompany.com.

Media Contact:
Public Policy Holding Company, Inc.
(202) 688-0020
inquiries@pphcompany.com

Investor Relations:
Matthew Mazzanti
(202) 559-0172
IR@pphcompany.com

Five-year facility refinances existing borrowings and provides additional capacity to support acquisitions and general corporate purposes

WASHINGTON, Nov. 02, 2026 (GLOBE NEWSWIRE) — Public Policy Holding Company, Inc. (“PPHC”, the “Group” or the “Company”) (Nasdaq: PPHC), a leading global strategic communications provider offering a comprehensive range of advisory services in Government Relations, Public Affairs and Corporate Communications, announces that it has entered into a new $105 million senior secured credit facility with a U.S. commercial bank (the “New Facility”).

The New Facility comprises a $65 million term loan and a $40 million revolving credit facility. The Group intends to seek commitments from additional lenders through a syndication to increase the New Facility to an aggregate $150 million. The New Facility may include an additional uncommitted accordion option of up to $50 million. Syndication is being undertaken on a best-efforts basis and is currently anticipated to close in January 2027.

Key Terms

• A five-year senior secured facility comprising a $65 million term loan and a $40 million revolving credit facility at initial closing.
• Expected syndication to a total facility size of $150 million, anticipated to close in January 2027 on a best-efforts basis.
• An uncommitted accordion option of up to an additional $50 million, subject to lender approval and the satisfaction of applicable conditions.
• Interest payable at the Secured Overnight Financing Rate (“SOFR”) plus a margin of 185 to 230 basis points, determined by the Group’s net leverage ratio. An unused commitment fee of 15 to 25 basis points applies to undrawn revolving commitments, also based on net leverage.
• Term loan amortization, stated as a percentage of the original balance, of 5.0% in each of years one and two, 7.5% in each of years three and four, and 10.0% in year five, with the remaining balance due at maturity on November 2, 2031. The revolving credit facility is interest only.
• Secured by a blanket lien over the Group’s assets, with guarantees from substantially all subsidiaries.

Use of Proceeds

The proceeds of the New Facility will be used to refinance the Group’s existing debt, fund acquisitions including an immediate drawdown to fund the initial cash consideration for the acquisition of Reevemark LLC announced earlier today and provide additional capacity for working capital and general corporate purposes.

Existing Facilities

The Group’s existing borrowings under the credit arrangements first announced on March 1, 2023, and subsequently expanded and amended on April 30, 2024, June 6, 2024, and January 24, 2025, will be repaid and replaced by the New Facility shortly after closing. As of September 30, 2026, approximately $39.8 million was outstanding under the existing facilities.

Capital Allocation

The New Facility consolidates the Group’s borrowings into a single financing structure on more favorable terms, extends the Group’s debt maturity profile, and provides additional capacity to support its growth strategy.

The Group intends to maintain a prudent leverage ratio as it combines organic growth with targeted, earnings-accretive M&A. The PPHC Board of Directors considers that access to both debt and equity funding provides appropriate flexibility in the Group’s capital allocation, including the funding of acquisitions and deferred consideration, as well as the payment of dividends.

Stewart Hall, CEO of PPHC, commented:

“This new facility strengthens our financial position and provides additional capacity to execute our growth strategy while maintaining a disciplined approach to leverage and capital allocation. We remain focused on deploying capital selectively into opportunities that enhance our capabilities, broaden our geographic reach and create long-term value for shareholders.”

B/T Advisory acted as exclusive debt advisor, and Venable LLP acted as legal counsel to the Group. Further details of the New Facility, including the identity of the lender and a copy of the credit agreement, will be set out in a Current Report on Form 8-K to be filed with the U.S. Securities and Exchange Commission, which will be available at www.sec.gov and on the Company’s investor relations website.

About PPHC

Incorporated in 2014, PPHC is a global strategic communications platform that supports clients in enhancing and defending their reputations, advancing policy objectives, managing regulatory risk, and engaging with federal and state-level policymakers, stakeholders, media, and the public.

Engaged by approximately 1,500 clients, including companies, trade associations and non-governmental organizations, PPHC is active in all major sectors of the economy, including healthcare and pharmaceuticals, financial services, energy, technology, telecommunications and transportation.

With operations across 18 offices in the United States and internationally, PPHC’s services include government relations, public affairs and corporate communications, research and analytics, digital advocacy campaigning, and compliance support. The Company’s shares are admitted to trading on the Nasdaq Global Market and on AIM, a market operated by the London Stock Exchange, under the ticker symbol “PPHC”.

For more information, visit www.pphcompany.com.

Media Contact:
Public Policy Holding Company, Inc.
(202) 688-0020
inquiries@pphcompany.com

Investor Relations:
Matthew Mazzanti
(202) 559-0172
IR@pphcompany.com

ANNOUNCEMENT

A.P. Møller – Mærsk A/S – Transactions in connection with share buy-back program

On 5 February 2026, A.P. Møller – Mærsk A/S (the “Company”) announced a share buy-back program of up to DKK 6.3bn (around USD 1bn) to be executed over a period of 12 months. The second phase of the share buy-back program will run from 13 August 2026 up to 29 January 2027. The shares to be acquired will be limited to a total market value of DKK 3.15 billion (around USD 500m).

The share buy-back program will be executed under EU Commission Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 (the “Safe Harbour Regulation”)

The following transactions have been made under the program in the period 26 October to 30 October 2026:   

	Number of A shares	Average purchase price A shares, DKK	Transaction value, A shares, DKK
Accumulated, last announcement	51,248		887,107,560
26 October 2026	220	22,860.7273	5,029,360
27 October 2026	220	22,905.0000	5,039,100
28 October 2026	220	22,811.1818	5,018,460
29 October 2026	220	22,888.9091	5,035,560
30 October 2026	220	22,607.2727	4,973,600
Total 26-30 October Friday	1,100		25,096,080
Accumulated in the second phase of the program	14,100		309,849,270
Accumulated under the program	52,348		912,203,640
	Number of B shares	Average purchase price B shares, DKK	Transaction value, B shares, DKK
Accumulated, last announcement (market and the Foundation)	204,992		3,639,922,058
26 October 2026	771	23,490.1816	18,110,930
27 October 2026	771	23,582.6459	18,182,220
28 October 2026	771	23,521.2711	18,134,900
29 October 2026	771	23,583.1128	18,182,580
30 October 2026	771	23,259.6368	17,933,180
Total 26-30 October Friday	3,855		90,543,810
Bought from the Foundation*	545	23,487.3696	12,800,616
Accumulated in the second phase of the program (market and the Foundation)	56,400		1,285,398,209
Accumulated under the program (market and the Foundation)	209,392		3,743,266,484

*) According to a separate agreement, A.P. Møller og Hustru Chastine Mc-Kinney Møllers Familiefond (the Foundation) participates on a pro rata basis to the shares purchased in the share buy-back program.

With the transactions stated above, the Company owns a total of 52,348 A shares and 266,522 B shares as treasury shares, corresponding to 2.17% of the share capital.        
Details of each transaction are included as appendix.

Copenhagen, 2 November 2026

Contact persons:
Head of Investor Relations, Martin Dunwoodie, tel. +45 3363 3484
Head of Media Relations, Jesper Lov, tel. +45 6114 1521

Page 1 of 1

Attachments

• Announcement – Transactions in connection with share buy-back program – week 44 2026
• Daily transactions in connection with share buy-back program – week 44 2026

LEI: 213800ZBKL9BHSL2K459

2 November 2026

OSB GROUP PLC

(the Company)

Notification of admission to trading

The Company announced today the following information in accordance with PRM 1.6.4R of the FCA’s Prospectus Rules: Admission to Trading on a Regulated Market sourcebook.

Details of issuer
(A) Name	OSB Group plc
(B) LEI	213800ZBKL9BHSL2K459
Details of the transferable securities admitted to trading
(A) Name, type and identification code	Ordinary shares of £0.01 each GB00BLDRH360
(B) Regulated Market	London Stock Exchange Main Market
(C) Number of further securities issued and admitted	15,233
(D) Total number of securities in issue following admission	335,364,143 (2,081,268 ordinary shares (not yet in issue) remain subject to the block admission).
(E) Fungibility	Fully fungible with existing ordinary shares.
Issue and admission details
(A) Date of issuance and admission	Issued on dates between 1 October 2026 – 31 October 2026 inclusive (admitted under the Company’s existing block admission)
(B) Coverage of notification	Admission of shares under the Company’s employee share schemes from 1 October 2026 up to 31 October 2026, admitted to trading on the Main Market of the London Stock Exchange under the Company’s existing block admission of shares.
(C) Prospectus	No prospectus was required in connection with the admissions.

Enquiries: Jason Elphick Group General Counsel and Company Secretary Email: Company.secretariat@osb.co.uk

Investor relations 

Alexander Holcroft
Group Director of Investor Relations
Email: osbrelations@osb.co.uk

Brunswick 

Robin Wrench / Simone Selzer t: 020 7404 5959

Notes to Editors

About OSB GROUP PLC

OSB began trading as a bank on 1 February 2011 and was admitted to the main market of the London Stock Exchange in June 2014 (OSB.L). OSB joined the FTSE 250 index in June 2015. On 4 October 2019, OSB acquired Charter Court Financial Services Group plc and its subsidiary businesses. On 30 November 2020, OSB GROUP PLC became the listed entity and holding company for the OSB Group. The Group provides specialist lending and retail savings and is authorised by the Prudential Regulation Authority, part of the Bank of England, and regulated by the Financial Conduct Authority and Prudential Regulation Authority. The Group reports under two segments, OneSavings Bank and Charter Court Financial Services.